Skip to Main Content

Tyme Technologies (TYME) sent out a press release Friday trumpeting that its cancer drug, SM-88, “improves survival” in a Phase 2 study of patients with advanced pancreatic cancer. However, the study raises two big red flags.

First, it is impossible to conclude that based on the study in question. Second, the results were less impressive on the main efficacy goal of the study.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED